On April 17, 2026, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Biosciences", stock code: 688321.SH) and its investee company, Chengdu Chipscreen Newway Biosciences Co., Ltd. (hereinafter referred to as "Chipscreen Newway Biosciences") announced that four preclinical research results from the company's self-developed oncology pipeline have been successfully selected for presentation at the 2026 American Association for Cancer Research (AACR) Annual Meeting in poster format.

This year's AACR Annual Meeting will be held from April 17 to 22, 2026, at the San Diego Convention Center in California, USA. The simultaneous selection of four studies from Chipscreen Biosciences and Chipscreen Newway Biosciences demonstrates the company's sustained innovation capability in innovative drugs and its rapid progress in the deployment of next-generation biologics. Representatives from Chipscreen Biosciences' U.S. subsidiary will attend the meeting to exchange ideas with researchers from the global industry and academia.

CS231295: Brain-Penetrant Aurora B Selective Inhibitor

• Abstract Title: CS231295, a Novel AURKB-Biased Multi-Kinase Inhibitor, Demonstrates Synthetic Lethality in RB1-Deficient Tumors and Potent Intracranial Efficacy

• Session Category: Small Molecule Therapeutic Agents

• Presentation Time: April 20, 14:00-17:00 (Local Time)

• Abstract Number: 3061

• Research Highlights: CS231295 is a potential "First-in-Class" brain-penetrant Aurora B selective multi-kinase inhibitor independently developed by Chipscreen Biosciences.Its unique synthetic lethality mechanism demonstrates significant therapeutic potential for RB1 gene-deficient tumors (such as small cell lung cancer), and the molecule also exhibits anti-tumor angiogenesis effects.Furthermore, CS231295 can effectively penetrate the blood-brain barrier, showing good inhibitory effects on intracranial tumors. Oral administration significantly promotes tumor regression in both RB1-deficient SCLC models and intracranial tumor models, providing strong support for its potential application in the treatment of RB1-deficient tumors and brain tumors. A Phase I clinical study of CS231295 is currently ongoing in China; the Investigational New Drug (IND) application of CS231295 was approved by the U.S. FDA, and its clinical trial in the United States is ready to proceed.

NW008: Dual-Functional ADC Targeting MICA/B

• Abstract Title: Preclinical Study of NW008, a Novel Dual-Functional Anti-MICA/B Antibody-Drug Conjugate

• Session Category: Experimental and Molecular Therapeutics

• Presentation Time: April 20, 09:00-12:00 (Local Time)

• Abstract Number: 1658

• Research Highlights: NW008 is a first-in-class, dual-functional anti-MICA/B antibody-drug conjugate (ADC) that combines immune restoration with TOP1i-mediated cytotoxicity; it demonstrates potent in vitro and in vivo anti-tumor activity in preclinical studies and exhibits favorable tolerability in cynomolgus monkeys at doses up to 60 mg/kg.

NW024-1: ADC Targeting ALPP/ALPP2

• Abstract Title: NW024-1, a novel ALPP/ALPPL2-targeting antibody drug conjugate with a topoisomerase 1 inhibitor payload, demonstrates potent antitumor efficacy

• Session Category: Experimental And Molecular Therapeutics, Drug discovery, Antibody technology

• Presentation Time: April 20, 09:00-12:00 (Local Time)

• Abstract Number: 1697

• Research Highlights: NW024-1 is a breakthrough candidate molecule of a TOP1i-ADC targeting ALPP/ALPPL2. NW024-1 binds with high specificity to ALPP/ALPPL2 on the surface of tumor cells and rapidly internalize, releasing the payload to induce DNA damage. In the gastric cancer NCI-N87 model, a single dose of 1.6 mg/kg achieved near-complete tumor regression (TGI=116.33%), with good tolerability in mice.Furthermore, the naked antibody NW024-mAb itself also exhibits ADCC and ADCP effects, achieving a dual anti-tumor mechanism mediated by both the antibody and the payload.

NW006-296: ADC Targeting ROR1

• Abstract Title: NW006-296, a novel ROR1 targeting ADC, demonstrates compelling anti-tumor efficacy in preclinical studies

• Session Category: Experimental and Molecular Therapeutics, Drug discovery, Antibody technology

• Presentation Time: April 21, 14:00-17:00 (Local Time)

• Abstract Number: 5645

• Research Highlights: NW006-296 is an ADC targeting ROR1.This molecule demonstrates potent in vitro killing activity against a variety of ROR1-positive tumor cells; in the U2932 CDX model, anti-tumor efficacy persisted for over 40 days following a single dose.Preliminary safety assessment showed no body weight loss in mice, indicating good tolerability, and pharmacokinetic data revealed advantages such as high ADC exposure and low free payload levels.

Chipscreen Biosciences has established a robust product portfolio in the field of oncology therapeutics. The core product, Chidamide (Epidaza^®), as the world's first subtype-selective HDAC inhibitor, has been approved for six indications in Mainland China, Taiwan (China), Macau (China), and Japan. The company and its partners are conducting global studies to explore the application of Chidamide in combination with cancer immunotherapies and are developing next-generation HDACi+IO drugs. The multi-targeted kinase inhibitor Chiauranib is currently being evaluated in multiple Phase III clinical studies. Currently, the company's oncology pipeline includes five projects in the clinical study stage.

The company has seamlessly integrated AI-assisted design technologies to build an "AI-assisted design + chemogenomics integrated technology platform," significantly improving the efficiency of early-stage new drug discovery. This has resulted in a 33% increase in drug design efficiency and a 40% enhancement in target binding energy after molecular optimization, thereby markedly accelerating the R&D process for innovative oncology drugs. Currently, Chipscreen Biosciences and Chipscreen Newway Biosciences have efficiently advanced multiple innovative drug candidates, including NW001 (an epigenetic-immune ADC candidate based on Chidamide), CS1008 (a next-generation multi-targeted kinase inhibitor targeting both FLT3 mutations and their resistance-related pathways), CDCS09 (epigenetic regulation), and CS08399 (a PRMT5-MTA inhibitor). Among these, CS08399 received clinical trial approval from the National Medical Products Administration in March 2026, intended for the treatment of MTAP-deleted solid tumors and lymphomas.